Image Source : IPO Watch
Anthem Biosciences’ blockbuster $395 million initial public offering (IPO) has been fully subscribed on the second day of bidding, underscoring strong investor confidence in India’s fastgrowing biotech sector. The Bengalurubased contract research and manufacturing firm is now poised to make its public market debut with momentum on its side.
Key Highlights:
-
The IPO received bids for 100% of the offered shares by Day 2, with retail and institutional segments showing robust demand.
-
Anthem is offering shares in the price band of Rs 1,155–1,225, with a minimum lot size of 12 shares.
-
The issue includes a fresh equity raise of Rs 1,000 crore and an offerforsale component by existing investors.
Business Profile:
-
Anthem Biosciences specializes in contract development and manufacturing for pharmaceuticals, biologics, and specialty chemicals.
-
Its clientele includes top global pharma firms, with operations spanning India, the US, and Europe.
-
The company reported Rs 1,200 crore in revenue for FY25, with EBITDA margins exceeding 30%.
Use of Proceeds:
-
Funds will be used to expand manufacturing capacity, invest in R&D infrastructure, and repay select borrowings.
-
Anthem plans to set up a new biologics facility in Hosur and upgrade its existing R&D campus in Bengaluru.
Market Sentiment:
-
Analysts view the IPO as a bellwether for India’s biotech listing pipeline, with several firms expected to follow suit.
-
The oversubscription reflects investor appetite for innovationdriven, exportoriented businesses.
Sources: Business Standard, Moneycontrol, Economic Times, Financial Express, BloombergQuint.
Advertisement
Advertisement